Multiple System Atrophy (MSA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
-1.jpg)
Multiple system atrophy (MSA) is a neurodegenerative disorder with a median survival of 6-9 years that is characterised by autonomic failure (cardiovascular and/or urinary), parkinsonism, cerebellar impairment, and corticospinal signs. · The incidence of MSA in the United States is estimated at 0.6 cases per 100,000 people per year in the general population giving a current estimate of about 1,900 new cases per year in the USA. · A prevalence study in London, UK, gave an age-adjusted figure of 4.4 living cases per 100,000 population at any one time, which would currently translate to about 14,000 living cases in the USA. Thelansis’s “Multiple System Atrophy (MSA) Market Outlook, Epidemiology , Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landsc...